If You Have PCOS, the Medical World Just Admitted It Got It Wrong 💊🫀
After 11 years, 22,000 people, and decades of women being misdiagnosed and dismissed, the medical world has finally admitted that the name was part of the problem.
If you have PCOS, or think you might, you will know the particular frustration of trying to explain it to someone who has never heard of it. You mention ovarian cysts and watch their face go blank. You try to describe something that touches your hormones, your weight, your skin, your mental health, your fertility, and you still get handed a leaflet about diet and exercise. The name never helped. It pointed people to the wrong place entirely.
That name is gone now. As of 12 May 2026, polycystic ovary syndrome is officially polyendocrine metabolic ovarian syndrome, PMOS, following a landmark consensus paper published in The Lancet. This was not a rebranding exercise. It was a rigorous, decade-long scientific process involving around 22,000 experts across the globe, doctors, researchers, patients, and advocacy groups, endorsed by over 56 major organisations worldwide. For a condition that has spent decades being minimised, that is not a small thing.
For decades, clinicians and patients noted that polycystic ovary syndrome was a misnomer. The name implied the presence of pathological ovarian cysts, which are not actually a feature of the condition. What appears on ultrasound are arrested follicles, not cysts. That single misrepresentation set the tone for everything that followed. Up to 70% of cases remain undiagnosed. Women were told they had a gynaecological problem when they actually had a hormonal and metabolic one. For many women in the UK, that meant years of going back and forth to their GP, being told their symptoms were unrelated, or simply not being believed. Prof Channa Jayasena, a reproductive endocrinologist at Imperial College London, welcomed the change, calling it a tremendous initiative and a great step forward in helping women and clinicians understand the full seriousness of the condition.
The new name does what the old one never could. Every word reflects something the old name ignored, the hormonal complexity, the metabolic impact on weight, insulin, and heart health, and the ovarian function that goes far deeper than the word cysts ever suggested. As Professor Helena Teede, who led the name change process, explained, ovarian encompasses far more than it has historically been given credit for. That is what women with this condition have been saying for years. The name just never reflected it.
The renaming is not symbolic. It comes with updates to clinical guidelines, medical education, and international disease classification systems. Here in the UK, 2026 has seen the launch of the renewed Women's Health Strategy for England, and the National Institute for Health and Care Excellence is expected to publish the first standalone guidelines for PMOS later this year. The NHS has also been urged to update its website, which currently makes no mention of the name change at all. As one advocate put it, communities deserve clear, accessible, and timely information so people are not left confused, excluded, or struggling to access support and diagnosis. Renaming the condition is the beginning, not the end.
Rachel Morman, Chair of Verity (PCOS UK) and a lived experience expert on the global name change process, said the previous name misrepresented the true nature of the condition. "It is fantastic that the new name now leads with hormones and recognises the metabolic dimension of the condition. This shift will reframe the conversation and demand that it is taken as seriously as the long-term, complex health condition it is." Melanie Cree, a paediatric endocrinologist involved in the international process, was equally direct. "Renaming this condition is more than semantics. It is about finally recognising the full reality of what patients experience."
PMOS affects more than 170 million people worldwide. One in eight women. Most of them waited far too long to understand what was actually happening in their own bodies, not because the information did not exist, but because the framing kept getting in the way. The name has changed. The conversation needs to follow.
The global consensus renaming PCOS to PMOS was published in The Lancet on 12 May 2026 and presented at the European Congress of Endocrinology in Prague.